Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
Kira BlankenbachNicholas SchwabBenjamin HofnerOrtwin AdamsBrigitte Keller-StanislawskiClemens WarnkePublished in: Neurology (2019)
JC polyomavirus DNA detection in CSF has limited sensitivity in early PML, and clinical and imaging presentation may be atypical. Thus, critical revision of current PML diagnostic criteria is warranted. Negative anti-JC polyomavirus antibodies in sera do not preclude the later development of PML. This emphasizes the need for close and regular serologic, imaging, and clinical monitoring in patients treated with natalizumab.